Connecting people, advancing clinical value
Connecting people, advancing clinical value
This is 69 Newsletter for November 2025. This article we focus at the growing gap between how much global pharma is investing in Korean R&D and how little Korean patients still access new medicines. In 2024, global companies ran 1,691…
Introduction Korea’s clinical‑trial ecosystem is quickly becoming a global hub. In 2026, triple‑agonist clinical trials in Korea will dominate metabolic research. The Ministry of Food and Drug Safety’s (MFDS) IND approval trends and regulatory reforms are accelerating these studies, and…